Citizens Jmp Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $4.00

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) had its price target decreased by research analysts at Citizens Jmp to $4.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a "market outperform" rating on the stock. Citizens Jmp's target price suggests a potential upside of 258.74% from the company's current price.

Several other analysts have also issued reports on the stock. Piper Sandler boosted their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. LADENBURG THALM/SH SH began coverage on shares of Compass Therapeutics in a research note on Wednesday, July 1st. They issued a "buy" rating and a $5.00 price objective for the company. Guggenheim lowered their target price on shares of Compass Therapeutics to $4.00 and set a "buy" rating on the stock in a report on Wednesday. Citigroup restated a "market outperform" rating on shares of Compass Therapeutics in a research report on Wednesday. Finally, Wedbush set a $4.00 price target on Compass Therapeutics in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.21.

Compass Therapeutics Trading Down 4.7%

Shares of CMPX stock traded down $0.06 on Wednesday, hitting $1.12. 2,191,480 shares of the stock were exchanged, compared to its average volume of 4,562,875. The firm's 50 day moving average is $2.12 and its two-hundred day moving average is $2.93. Compass Therapeutics has a one year low of $1.10 and a one year high of $6.88. The firm has a market capitalization of $200.80 million, a PE ratio of -2.79 and a beta of 0.95.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, sell-side analysts expect that Compass Therapeutics will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Compass Therapeutics during the second quarter valued at $24,707,000. Palo Alto Investors LP bought a new position in Compass Therapeutics in the 2nd quarter worth about $12,771,670. BVF Inc. IL raised its holdings in shares of Compass Therapeutics by 63.5% in the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company's stock valued at $41,697,000 after acquiring an additional 3,014,842 shares in the last quarter. Sofinnova Investments Inc. raised its holdings in shares of Compass Therapeutics by 65.9% in the 4th quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company's stock valued at $18,072,000 after acquiring an additional 1,336,560 shares in the last quarter. Finally, NEXTBio Capital Management LP bought a new stake in shares of Compass Therapeutics during the 4th quarter valued at about $5,982,000. Institutional investors own 68.43% of the company's stock.

Trending Headlines about Compass Therapeutics

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Compass said it intends to continue pursuing a regulatory filing for tovecimig despite the FDA’s request for a new trial, preserving a potential path toward approval if the company can address the agency’s concerns. Compass vows to press on with FDA application despite new trial request
• Positive Sentiment: Citizens JMP maintained a market outperform rating and set a $4 price target, implying substantial upside from recent trading levels. However, the target was reduced, reflecting greater uncertainty around the program.
• Neutral Sentiment: An analysis characterized Compass’s opportunity as promising but facing a shrinking window, highlighting the importance of quickly resolving the FDA’s clinical and regulatory requirements. Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity
• Negative Sentiment: The FDA recommended an additional survival-focused trial in biliary tract cancer before or alongside a potential marketing filing for tovecimig. Investors are concerned that the requirement could delay development, increase costs and potentially require additional financing. Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer
• Negative Sentiment: Wedbush downgraded CMPX from Outperform to Neutral and cut its price target from $5 to $1, calling the filing strategy risky. LifeSci Capital also downgraded the stock from Strong Buy to Hold. These actions reinforce concerns about regulatory timing and the probability of near-term value creation. Wedbush Downgrades Compass Therapeutics

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company's research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.